RhoVac AB receives approval to start clinical phase IIb study in Denmark
RhoVac AB ("RhoVac") announces today, June 5, 2019, that the Danish Medicines Agency (DMA) has approved RhoVac's clinical trial application (CTA) on the clinical phase IIb study with the drug candidate RV001. The approval from the DMA is conditioned final approval by the Ethics Committee, which has not yet finalized the review of the application.Clinical Phase IIb study The study, named RhoVac-002 ("BRAVAC") for which RhoVac has received approval to start, targets prostate cancer patients who have completed primary treatment (surgery or radiotherapy) and who show rising values in the